POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myelofibrosis anemia: experimental drug enters human trials
Disease control OngoingThis early-stage trial tests an experimental drug called INCB000928, given alone or with the standard drug ruxolitinib, for people with myelofibrosis who have severe anemia or need regular blood transfusions. The main goals are to check the drug's safety, find the right dose, and…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can an arthritis drug tame a rare bone marrow cancer?
Disease control OngoingThis phase 2 trial tests canakinumab, an anti-inflammatory drug, in 14 to 26 people with myelofibrosis, a rare bone marrow cancer that causes scarring, enlarged spleen, and fatigue. Participants receive injections every three weeks for about six months. The study checks if the dr…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for myelofibrosis patients with dangerous low platelet counts
Disease control OngoingThis phase 3 study tests a drug called pacritinib against standard treatments chosen by the doctor in people with myelofibrosis who have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and reduce symptoms like tiredness, pain, and i…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo pill shows promise for rare bone marrow cancer
Disease control OngoingThis Phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not had prior JAK inhibitor treatment will take either the combination or …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC